MediciNova, Inc. (MNOV) Stock Forecast
MNOV analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $8.25 average of analyst targets
- Upside to target
- +481.0% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.06
- 52-week range
- $1.18 – $3.45
MNOV analyst ratings
4 analystsNumber of analysts at each rating.
MNOV price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MNOV earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.06 | −$0.06 | −$0.06 | 0.0% | 3 |
| Current fiscal year (2026) | −$0.26 | −$0.28 | −$0.23 | −$0.24 | −7.0% | 3 |
| Next fiscal year (2027) | −$0.52 | −$0.58 | −$0.45 | −$0.26 | −100.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MNOV revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $50,000 | $0 | $150,000 | −59.5% | 3 |
| Current fiscal year (2026) | $730,000 | $645,000 | $900,000 | +78.2% | 3 |
| Next fiscal year (2027) | $333,330 | $0 | $1.0M | −54.3% | 3 |
MNOV EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MNOV revenue: reported and forecast
MNOV EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.06 | −$0.06 | −$0.06 | −$0.06 | 0.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.26 | −$0.26 | −$0.28 | −$0.26 | −$0.26 | −1.3% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.43 | −$0.43 | −$0.45 | −$0.52 | −$0.52 | +19.8% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MNOV earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MNOV beat in 10 of 12.
What analysts expect from MNOV
4 analysts cover MediciNova; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.25, 481.0% above the latest close of $1.42. Analysts expect earnings of −$0.26 per share for 2026, −7.0% from a year earlier. For 2027 the average estimate is −$0.52 per share on revenue of $0.3 million. MediciNova beat the EPS estimate in 10 of the last 12 quarters.
Related: MNOV income statement, MNOV key metrics, MNOV chart. See the MNOV stock overview for the latest quote and news.
MNOV forecast FAQ
What is MediciNova's price target?
The average analyst price target for MediciNova is $8.25, 481.0% above the latest close of $1.42.
Is MediciNova a buy, hold or sell?
Of 4 analysts covering MediciNova, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is MediciNova's EPS forecast?
Analysts forecast −$0.26 per share for 2026 (range −$0.28 to −$0.23); for 2027 the estimate is −$0.52.
What is MediciNova's revenue forecast?
The average revenue estimate for 2026 is $0.7 million, growth of 78.2%; for 2027 it is $0.3 million.
When does MediciNova report earnings?
MediciNova is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.06.
Does MediciNova usually beat earnings estimates?
MediciNova reported EPS at or above the analyst estimate in 10 of the last 12 quarters.